Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
Successful Treatment of MDR and XDR-TB
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Since it was first described by international health organizations in 2006, extensively drug-resistant tuberculosis has been documented in 49 countries. In addition, more than 80 countries are coping with multi-drug resistant tuberculosis. How are we addressing the rapid emergence of these significant threats to tuberculosis treatment and control programs across the world? In which countries are we seeing significant progress in treating both forms of tuberculosis? Dr. Sonya Shin, assistant professor of medicine at Harvard Medical School, contours lessons for the global struggle against TB from her work in South America and Asia with host Dr. Mark Nolan Hill.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
CME/CE
Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy
0.25 credits
<p>Implementing a Multidisciplinary Approach to Heart Failure: Patient Identification and Treatment Using Novel Device Therapy</p>
CME/CE
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
0.50 credits
<p>IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement</p>
CME/CE
IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue
0.50 credits
<p>IgG4-RD Case Conversations: Using Thoracic CT as a Diagnostic Clue</p>
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
MinuteCE®
Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA
1.25 credits
<p>Clinical Conundrums in ARIA: Nuances of Microhemorrhages when Evaluating an MRI for ARIA</p>
MinuteCE®
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
1.25 credits
<p>Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
CME/CE
Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers
1.00 credits
<p>Establishing Best Practices for Collaborative Care for Patients with ASCVD Between Academic and Rural Providers</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?